Dexcom Promotes CGM As First-Line Tool In Type 2 Diabetes

Company Combines Education, Advocacy And Clinical Studies To Shift Standard Of Treatment.

Only 14% of people with type 2 diabetes use continuous glucose monitors, although 93% of users report a positive impact on their health. Dexcom is ramping up efforts to close this adoption gap.

One of the most significant is the Steno2Tech study, a 12-month, single-center, randomized controlled trial conducted at the Steno Diabetes Center, Copenhagen, Denmark

More from Diabetic Care

More from Medtech Insight